微波消融联合仑伐替尼及HAIC或TACE治疗进展期HCC的疗效与安全性比较-现代医学

微波消融联合仑伐替尼及HAIC或TACE治疗进展期HCC的疗效与安全性比较

作者：赵敬兵¹ 钟晓蓉² 汪杰¹ 李钊¹ 吴建林¹ 龚应年¹ 余峰¹ 周国俊¹ 冷政伟¹ 2

单位：1. 川北医学院附属医院肝胆外科, 四川南充 637000;
2. 川北医学院肝胆胰肠疾病研究所, 四川南充 637000

分类号：R657.3

出版年·卷·期（页码）：2024·52·第六期（892-899）

摘要：

目的： 对比微波消融术(MWA)联合仑伐替尼及肝动脉灌注化疗(HAIC)与肝动脉化疗栓塞术(TACE)治疗进展期原发性肝细胞性肝癌(HCC)的疗效与安全性。方法： 采用回顾性评价方法，收集2019年10月至2022年10月于川北医学院附属医院接受MWA联合仑伐替尼及HAIC或TACE联合治疗进展期HCC的96例患者临床病例资料。其中MWA联合仑伐替尼及HAIC方案治疗的患者43例，MWA联合仑伐替尼及TACE方案治疗的患者53例。根据mRECIST评价标准评估客观缓解率(ORR)、疾病控制率(DCR)、不良事件发生发生率、无疾病进展生存期(PFS)和总生存期(OS)。结果： HAIC联合治疗组43例患者总体疗效评价ORR为67.4%，DCR为84.4%。TACE联合治疗组53例患者总体疗效评价ORR为32.1%，DCR为69.8%。HAIC联合治疗组、TACE联合治疗组中位PFS分别为13个月(95%CI 8～18)、9个月(95%CI 7.2～10.8)(P=0.042)。两组患者中位OS分别为18个月(95%CI 11～25)、14个月(95%CI 10.7～17.3)(P=0.342)。HAIC联合治疗组主要不良反应为呕吐、腹痛、下肢静脉血栓及化疗相关骨髓抑制，TACE联合治疗组主要不良反应为发热、腹痛、肝功能异常及血小板减少，并且两组患者均无治疗相关死亡事件。结论： MWA联合仑伐替尼及HAIC治疗进展期HCC相比于MWA联合仑伐替尼及TACE组治疗进展期HCC有更高的PFS，且不良反应发生率更低。

Objective: To compare the efficacy and safety of microwave ablation(MWA) combined with lenvatinib and hepatic artery infusion chemotherapy(HAIC) with hepatic artery chemoembolization(TACE) for the treatment of progressive primary hepatocellular carcinoma(HCC). Methods: Clinical case data of 96 patients who received MWA combined with lenvatinib and HAIC or TACE combined for the treatment of progressive HCC at the Affiliated Hospital of Chuanbei Medical College from October 2019 to October 2022 were collected using a retrospective evaluation method. Among them, 43 patients were treated with MWA combined with lenvatinib and HAIC regimen, and 53 patients were treated with MWA combined with lenvatinib and TACE regimen. Objective remission rate(ORR), disease control rate(DCR), incidence of adverse events, disease progression-free survival(PFS) and overall survival(OS) were assessed according to mRECIST evaluation criteria. Results: The overall efficacy evaluation ORR was 67.4% and DCR was 84.4% for 43 patients in the HAIC combination therapy group. The overall efficacy evaluation ORR was 32.1% and DCR was 69.8% for 53 patients in the TACE combination therapy group. The median PFS for the HAIC combination therapy group and the TACE combination therapy group was 13 months(95%CI 8-18), 9 months(95%CI 7.2-10.8)(P=0.042). The median OS was 18 months(95%CI 11-25) and 14 months(95%CI 10.7-17.3) in the two groups, respectively(P=0.342). Major adverse effects in the HAIC combination therapy group were vomiting, abdominal pain, lower extremity venous thrombosis and chemotherapy-related bone marrow suppression, while the major adverse effects in the TACE combination therapy group were fever, abdominal pain, liver function abnormalities and thrombocytopenia. And there were no treatment-related deaths in both groups. Conclusion: MWA combined with lenvatinib and HAIC for the treatment of progressive HCC had a higher PFS and a lower incidence of adverse events than MWA combined with lenvatinib and TACE for the treatment of progressive HCC.

参考文献：

[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] 鲜林峰，方乐天，刘文斌，等.原发性肝癌流行现状、主要发病机制及防控策略[J].中国癌症防治杂志，2022，14(3)：320-328.
[3] ANDO E,TANAKA M,YAMASHITA F,et al.Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis:analysis of 48 cases[J].Cancer,2002,95(3):588-595.
[4] PARK J Y,AHN S H,YOON Y J,et al.Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma[J].Cancer,2007,110(1):129-137.
[5] 李艳民，王林林，周言.TACE联合RFA治疗不同BCLC分期原发性肝癌的疗效及安全性研究[J].东南大学学报(医学版)，2021，40(3)：353-359.
[6] DUAN X,LI H,KUANG D,et al.Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma:a multicenter retrospective cohort study[J].Hepatol Int,2023,17(4):915-926.
[7] HAN T,YANG X,ZHANG Y,et al.The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma:a Meta-analysis[J].Biosci Trends,2019,13(5):374-381.
[8] VOGL T J,NOUR-ELDIN N A,HAMMERSTINGL R M,et al.Microwave ablation(MWA):basics,technique and results in primary and metastatic liver neoplasms—review article[J].Rofo,2017,189(11):1055-1066.
[9] LUERKEN L,HAIMERL M,DOPPLER M,et al.Update on percutaneous local ablative procedures for the treatment of hepatocellular carcinoma[J].Rofo,2022,194(10):1075-1086.
[10] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版)[J].中华普通外科学文献(电子版)，2022，16(2)：81-96.
[11] GAO S,ZHANG P J,GUO J H,et al.Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients[J].World J Gastroenterol,2015,21(36):10443-10452.
[12] APISAMTHHANARAX S,BARRY A,CAO M,et al.External beam radiation therapy for primary liver cancers:an ASTRO clinical practice guideline[J].Pract Radiat Oncol,2022,12(1):28-51.
[13] OYAMA A,NOUSO K,YOSHIMURA K,et al.Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma[J].Hepatol Res,2021,51(6):694-701.
[14] 王楠，薛国亮，徐静雯，等.微波消融在载药微球经肝动脉化疗栓塞术联合靶向和免疫治疗进展期原发性肝癌中的应用[J].中华肿瘤防治杂志，2023，30(14)：865-870.
[15] 钱嘉，张雷，吴楠.108例铂类化疗药致药品不良反应报告分析[J].中国医院用药评价与分析，2021，21(8)：1014-1016.
[16] 广东省药学会.铂类药物临床应用与不良反应管理专家共识[J].今日药学，2019，29(9)：577-585.
[17] KIM D Y,TOAN B N,TAN C K,et al.Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region[J].Clin Mol Hepatol,2023,29(2):277-292.
[18] LLOVET J M,LENCIONI R.mRECIST for HCC:Performance and novel refinements[J].J Hepatol,2020,72(2):288-306.
[19] FREITES-MARTINEZ A,SANTANA N,ARIAS-SANTIAGO S,et al.Using the common terminology criteria for adverse events(CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies[J].Actas Dermosifiliogr(Engl Ed),2021,112(1):90-92.
[20] 刘红艳, 王坤远, 樊蓉, 等. 十年磨一剑：肝细胞癌诊疗新进展[J].中华肝脏病杂志, 2021,29(2):111-115.
[21] ZHOU H,SONG T.Conversion therapy and maintenance therapy for primary hepatocellular carcinoma[J].Biosci Trends,2021,15(3):155-160.
[22] ZHAO M,GUO Z,ZOU Y H,et al.Arterial chemotherapy for hepatocellular carcinoma in China:consensus recommendations[J].Hepatol Int,2024,18(1):4-31.
[23] LIN Z,CHEN D,HU X,et al.Clinical efficacy of HAIC(FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs.TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas[J].Am J Cancer Res,2023,13(11):5455-5465.
[24] LI S,LYU N,HAN X,et al.Hepatic artery infusion chemotherapy using fluorouracil,leucovorin,and oxaliplatin versus transarterial chemoembolization as initial treatment for locally advanced hepatocellular carcinoma:a propensity score-matching analysis[J].J Vasc Interv Radiol,2021,32(9):1267-1276.
[25] IZZO F,RANATA V,GRASSI R,et al.Radiofrequency Ablation and Microwave Ablation in Liver Tumors:An Update[J].Oncologist,2019,24(10):e990-e1005.
[26] 李猛，陆荫英，董景辉，等.经肝动脉化疗栓塞术联合微波消融治疗中晚期原发性肝癌的效果分析[J].临床肝胆病杂志，2020，36(12)：2720-2724.
[27] 刘鹏辉，仲斌演，张帅，等.经动脉化疗栓塞同步微波消融与序贯联合微波消融治疗肝细胞癌的预后对比[J].肝胆胰外科杂志，2023，35(4)：213-218.
[28] 朱斌，周彬.肝动脉化疗栓塞联合B超引导下微波消融治疗原发性肝癌患者的临床研究[J].中国临床药理学杂志，2023，39(8)：1077-1081.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录